About Kymeratx
Kymeratx is a company based in Cambridge (United States) founded in 2016 by Nello Mainolfi and Steven Robinette.. Kymeratx has raised $197 million across 4 funding rounds from investors including Bessemer Venture Partners, BlackRock and Atlas Venture. The company has 188 employees as of December 31, 2024. Kymeratx offers products and services including KT-621 and Pipeline Therapeutics. Kymeratx operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Revolution Medicines, Blueprint Medicines and Syndax, among others.
- Headquarter Cambridge, United States
- Employees 188 as on 31 Dec, 2024
- Founders Nello Mainolfi, Steven Robinette
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kymera Therapeutics, Inc.
-
Annual Revenue
$47.07 M-40.11as on Dec 31, 2024
-
Net Profit
$-223.86 M-52.32as on Dec 31, 2024
-
EBITDA
$-249.34 M-53.94as on Dec 31, 2024
-
Total Equity Funding
$197 M (USD)
in 4 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Aug 19, 2022
-
Investors
Bessemer Venture Partners
& 19 more
-
Employee Count
188
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kymeratx
Kymeratx is a publicly listed company on the NASDAQ with ticker symbol KYMR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Kymeratx
Kymeratx offers a comprehensive portfolio of products and services, including KT-621 and Pipeline Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral degrader for treating Atopic Dermatitis and related conditions.
First-in-class medicines targeting disease drivers.
Unlock access to complete
Unlock access to complete
Leadership Team
66 people
Product Management Team
10 people
Software Development Team
9 people
Senior Team
9 people
Principal Team
7 people
Scientific Team
7 people
Operations Team
7 people
Human Resources and Administration
6 people
Unlock access to complete
Funding Insights of Kymeratx
Kymeratx has successfully raised a total of $197M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $150.0M
-
First Round
First Round
(30 Oct 2017)
- Investors Count 20
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Post-IPO - Kymeratx | Valuation |
investors |
|
| Mar, 2020 | Amount | Series C - Kymeratx | Valuation | Redmile Group , Foresite Capital | |
| Nov, 2018 | Amount | Series B - Kymeratx | Valuation | 6 Dimensions Capital , Bessemer Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kymeratx
Kymeratx has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Bessemer Venture Partners, BlackRock and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kymeratx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kymeratx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kymeratx Comparisons
Competitors of Kymeratx
Kymeratx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Revolution Medicines, Blueprint Medicines and Syndax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kymeratx
Frequently Asked Questions about Kymeratx
When was Kymeratx founded?
Kymeratx was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Kymeratx located?
Kymeratx is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Kymeratx?
Nello Mainolfi is the current CEO of Kymeratx. They have also founded this company.
Is Kymeratx a funded company?
Kymeratx is a funded company, having raised a total of $197M across 4 funding rounds to date. The company's 1st funding round was a Series B of $65M, raised on Oct 30, 2017.
How many employees does Kymeratx have?
As of Dec 31, 2024, the latest employee count at Kymeratx is 188.
What is the annual revenue of Kymeratx?
Annual revenue of Kymeratx is $47.07M as on Dec 31, 2024.
What does Kymeratx do?
Kymeratx was founded in 2016 in Cambridge, United States, within the biotechnology sector. Small molecule protein degraders are developed to target IRAK4, IRAKIMiD, and STAT3, addressing immune-inflammatory diseases, hematologic malignancies, and solid tumors. Targeted protein degradation platforms are provided, based on the ubiquitin-proteasome systems role in cellular regulation. Operations focus on therapeutic applications for these conditions.
Who are the top competitors of Kymeratx?
Kymeratx's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
What products or services does Kymeratx offer?
Kymeratx offers KT-621 and Pipeline Therapeutics.
Is Kymeratx publicly traded?
Yes, Kymeratx is publicly traded on NASDAQ under the ticker symbol KYMR.
Who are Kymeratx's investors?
Kymeratx has 20 investors. Key investors include Bessemer Venture Partners, BlackRock, Atlas Venture, Aju IB Investment, and Redmile Group.
What is Kymeratx's ticker symbol?
The ticker symbol of Kymeratx is KYMR on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.